JBIO

Jade is a clinical-stage biopharma with zero revenue in every year on record (net loss widening from -$23M in FY2021 to -$127M in FY2025) and no approved product. The entire investment case rests on a three-asset pipeline led by JADE101, a half-life-extended anti-APRIL mAb for IgA nephropathy that only entered a Phase 1 healthy-volunteer trial in August 2025. There is no human efficacy data yet — the MD&A itself frames JADE101's edge as preclinical potency and NHP pharmacokinetic advantages 'compared to sibeprenlimab,' a competitor already far ahead in the clinic. That is textbook unknowable, binary risk, and at ~49.3M shares the ~$21.51 price implies a market cap near $1.1B against just $333M of book equity — roughly $700M ascribed to unproven pipeline.

What keeps this a hold rather than an avoid is a genuinely fortress-like balance sheet for a company this early. Total liabilities are only $17.3M against $333M of stockholders' equity (liabilities/equity 0.05x), current assets of $349M dwarf $16.5M of current liabilities, and the FY2025 equity jump (assets +380%, a near-vertical equity increase) reflects a large recent capital raise/business-combination. Against an operating cash burn of -$94.7M, that liquidity buys multiple years of runway and materially lowers near-term financing risk — a real differentiator versus most pre-revenue biotechs.